Afatinib Plus Bevacizumab After Acquired Resistance to EGFR-TKI in EGFR-mutant NSCLC

Trial Profile

Afatinib Plus Bevacizumab After Acquired Resistance to EGFR-TKI in EGFR-mutant NSCLC

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Dec 2017

At a glance

  • Drugs Afatinib (Primary) ; Bevacizumab
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms ABC-study
  • Most Recent Events

    • 24 Dec 2017 Status changed from recruiting to completed.
    • 02 Jun 2017 Results (n=33) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 11 Dec 2014 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top